Blog Archive
-
▼
2010
(63)
-
▼
July
(6)
- Ligand Acquired Milestone and Royalty Interest in ...
- Radiometer : ABL800 FLEX reduces risk of misdiagno...
- SonarMed : FDA clearance for respiratory product
- Pulmonx : $32 Million for Launch of Emphysema Prod...
- Nycomed’s novel anti-inflammatory therapy Daxas® (...
- Kitware and Lung Cancer Alliance : First Publicly ...
-
▼
July
(6)
Jul 14, 2010
Pulmonx : $32 Million for Launch of Emphysema Products
February 22, 2010 - Emerging Interventional Pulmonology Leader Commences Rollout of Breakthrough New Products – Pulmonx, an emerging leader in interventional pulmonology, announced that it has concluded an agreement for a new round of equity financing from an investment syndicate led by two new investors. The company also announced that it plans to use this capital to support the international commercial launch of its Zephyr® Endobronchial Valve (EBV), and its recently approved Chartis® Pulmonary Assessment System. Both products are CE marked and cleared for sale in Europe and other major international markets. The company expects that this round of financing will fund the expansion of its commercial operations through to positive cash flow and profitability... [PDF] Pulmonx's Press Release -